GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pentixapharm Holding AG (XTER:PTP) » Definitions » Interest Coverage

Pentixapharm Holding AG (XTER:PTP) Interest Coverage : 0 (At Loss) (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Pentixapharm Holding AG Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Pentixapharm Holding AG's Operating Income for the six months ended in Dec. 2024 was €-15.59 Mil. Pentixapharm Holding AG's Interest Expense for the six months ended in Dec. 2024 was €0.04 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Pentixapharm Holding AG's Interest Coverage or its related term are showing as below:


XTER:PTP's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 119.89
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Pentixapharm Holding AG Interest Coverage Historical Data

The historical data trend for Pentixapharm Holding AG's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Pentixapharm Holding AG Interest Coverage Chart

Pentixapharm Holding AG Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Interest Coverage
- No Debt - -

Pentixapharm Holding AG Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24
Interest Coverage Get a 7-Day Free Trial No Debt No Debt - - -

Competitive Comparison of Pentixapharm Holding AG's Interest Coverage

For the Biotechnology subindustry, Pentixapharm Holding AG's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pentixapharm Holding AG's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pentixapharm Holding AG's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Pentixapharm Holding AG's Interest Coverage falls into.


;
;

Pentixapharm Holding AG Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Pentixapharm Holding AG's Interest Coverage for the fiscal year that ended in Dec. 2024 is calculated as

Here, for the fiscal year that ended in Dec. 2024, Pentixapharm Holding AG's Interest Expense was €-0.05 Mil. Its Operating Income was €-17.58 Mil. And its Long-Term Debt & Capital Lease Obligation was €0.00 Mil.

Pentixapharm Holding AG did not have earnings to cover the interest expense.

Pentixapharm Holding AG's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Here, for the six months ended in Dec. 2024, Pentixapharm Holding AG's Interest Expense was €0.04 Mil. Its Operating Income was €-15.59 Mil. And its Long-Term Debt & Capital Lease Obligation was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Pentixapharm Holding AG  (XTER:PTP) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Pentixapharm Holding AG Interest Coverage Related Terms

Thank you for viewing the detailed overview of Pentixapharm Holding AG's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Pentixapharm Holding AG Business Description

Traded in Other Exchanges
Address
Robert-Rossle-Street 10, Berlin, DEU
Pentixapharm Holding AG is a clinical-stage biopharmaceutical company active in the field of research and development of radiopharmaceuticals for diagnostic and therapeutic applications. Radiopharmaceuticals are medical substances containing radioactive elements used in nuclear medicine to diagnose or treat diseases. Its clinical pipeline encompasses PentixaTher, a Yttrium-90 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68-based companion diagnostic.

Pentixapharm Holding AG Headlines

No Headlines